Max W Adelman1,2, Chris W Bower2,3,4, Julian E Grass5, Uzma A Ansari5, Elizabeth A Soda5, Isaac See5, Joseph D Lutgring5, Jesse T Jacob1,2,6,7. 1. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. 2. Georgia Emerging Infections Program, Decatur, Georgia, USA. 3. Atlanta VA Medical Center, Decatur, Georgia, USA. 4. Foundation for Atlanta Veterans Education and Research, Decatur, Georgia, USA. 5. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 6. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia, USA. 7. Emory Antibiotic Research Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Abstract
BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) are highly antibiotic-resistant bacteria. Whether CRE resistant only to ertapenem among carbapenems (ertapenem "mono-resistant") represent a unique CRE subset with regards to risk factors, carbapenemase genes, and outcomes is unknown. METHODS: We analyzed surveillance data from 9 CDC Emerging Infections Program (EIP) sites. A case was the first isolation of a carbapenem-resistant Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, K. oxytoca, K. pneumoniae, or K. variicola from a normally sterile site or urine in an EIP catchment area resident in 2016-2017. We compared risk factors, carbapenemase genes, antibiotic susceptibility, and mortality of ertapenem "mono-resistant" cases to "other" CRE cases (resistant to ≥1 carbapenem other than ertapenem) and analyzed risk factors for mortality. RESULTS: Of 2009 cases, 1249 (62.2%) were ertapenem-mono-resistant and 760 (37.8%) were other CRE. Ertapenem-mono-resistant CRE cases were more frequently ≥80 years old (29.1% vs 19.5%; P < .0001) and female (67.9% vs 59.0%; P < .0001). Ertapenem-mono-resistant isolates were more likely to be Enterobacter cloacae complex (48.4% vs 15.4%; P < .0001) but less likely to be isolated from a normally sterile site (7.1% vs 11.7%; P < .01) or to have a carbapenemase gene (2.4% vs 47.4%; P < .0001). Ertapenem-mono-resistance was not associated with 90-day mortality in logistic regression models. Carbapenemase-positive isolates were associated with mortality (odds ratio, 1.93; 95% CI, 1.30-2.86). CONCLUSIONS: Ertapenem-mono-resistant CRE rarely have carbapenemase genes and have distinct clinical and microbiologic characteristics from other CRE. These findings may inform antibiotic choice and infection prevention practices, particularly when carbapenemase testing is not available.
BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) are highly antibiotic-resistant bacteria. Whether CRE resistant only to ertapenem among carbapenems (ertapenem "mono-resistant") represent a unique CRE subset with regards to risk factors, carbapenemase genes, and outcomes is unknown. METHODS: We analyzed surveillance data from 9 CDC Emerging Infections Program (EIP) sites. A case was the first isolation of a carbapenem-resistant Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, K. oxytoca, K. pneumoniae, or K. variicola from a normally sterile site or urine in an EIP catchment area resident in 2016-2017. We compared risk factors, carbapenemase genes, antibiotic susceptibility, and mortality of ertapenem "mono-resistant" cases to "other" CRE cases (resistant to ≥1 carbapenem other than ertapenem) and analyzed risk factors for mortality. RESULTS: Of 2009 cases, 1249 (62.2%) were ertapenem-mono-resistant and 760 (37.8%) were other CRE. Ertapenem-mono-resistant CRE cases were more frequently ≥80 years old (29.1% vs 19.5%; P < .0001) and female (67.9% vs 59.0%; P < .0001). Ertapenem-mono-resistant isolates were more likely to be Enterobacter cloacae complex (48.4% vs 15.4%; P < .0001) but less likely to be isolated from a normally sterile site (7.1% vs 11.7%; P < .01) or to have a carbapenemase gene (2.4% vs 47.4%; P < .0001). Ertapenem-mono-resistance was not associated with 90-day mortality in logistic regression models. Carbapenemase-positive isolates were associated with mortality (odds ratio, 1.93; 95% CI, 1.30-2.86). CONCLUSIONS: Ertapenem-mono-resistant CRE rarely have carbapenemase genes and have distinct clinical and microbiologic characteristics from other CRE. These findings may inform antibiotic choice and infection prevention practices, particularly when carbapenemase testing is not available.
Authors: April M Bobenchik; Eszter Deak; Janet A Hindler; Carmen L Charlton; Romney M Humphries Journal: J Clin Microbiol Date: 2014-12-24 Impact factor: 5.948
Authors: David van Duin; Cesar A Arias; Lauren Komarow; Liang Chen; Blake M Hanson; Gregory Weston; Eric Cober; Omai B Garner; Jesse T Jacob; Michael J Satlin; Bettina C Fries; Julia Garcia-Diaz; Yohei Doi; Sorabh Dhar; Keith S Kaye; Michelle Earley; Andrea M Hujer; Kristine M Hujer; T Nicholas Domitrovic; William C Shropshire; An Dinh; Claudia Manca; Courtney L Luterbach; Minggui Wang; David L Paterson; Ritu Banerjee; Robin Patel; Scott Evans; Carol Hill; Rebekka Arias; Henry F Chambers; Vance G Fowler; Barry N Kreiswirth; Robert A Bonomo Journal: Lancet Infect Dis Date: 2020-03-06 Impact factor: 25.071
Authors: Nora Chea; Sandra N Bulens; Thiphasone Kongphet-Tran; Ruth Lynfield; Kristin M Shaw; Paula Snippes Vagnone; Marion A Kainer; Daniel B Muleta; Lucy Wilson; Elisabeth Vaeth; Ghinwa Dumyati; Cathleen Concannon; Erin C Phipps; Karissa Culbreath; Sarah J Janelle; Wendy M Bamberg; Alice Y Guh; Brandi Limbago; Alexander J Kallen Journal: Emerg Infect Dis Date: 2015-09 Impact factor: 6.883
Authors: Jessica Martin; Hang T T Phan; Jacqueline Findlay; Nicole Stoesser; Louise Pankhurst; Indre Navickaite; Nicola De Maio; David W Eyre; Giles Toogood; Nicolas M Orsi; Andrew Kirby; Nicola Young; Jane F Turton; Robert L R Hill; Katie L Hopkins; Neil Woodford; Tim E A Peto; A Sarah Walker; Derrick W Crook; Mark H Wilcox Journal: J Antimicrob Chemother Date: 2017-11-01 Impact factor: 5.790